{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:01:01Z","timestamp":1790395261251,"version":"4.1.0"},"reference-count":37,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,9,25]]},"DOI":"10.1253\/circj.cj-25-1129","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:08:17Z","timestamp":1771020497000},"page":"1326-1335","source":"Crossref","is-referenced-by-count":2,"title":["Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis"],"prefix":"10.1253","volume":"90","author":[{"given":"Tsuyoshi","family":"Shirai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Tohoku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyasu","family":"Yoshida","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center, Kao Autoimmunity Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Sugano","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Hiwa","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Ishihara","sequence":"first","affiliation":[{"name":"Department of Clinical Rheumatology, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kida","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tazuke Kofukai Medical Research Institute, Kitano Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shimane University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Kadoba","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Yokohama City University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Kidoguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoyo","family":"Kiko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Fujita Health University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Nakagama","sequence":"additional","affiliation":[{"name":"Department of Virology, Graduate School of Medicine, Osaka Metropolitan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sanada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kanazawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ya","family":"Tamechika","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital"},{"name":"Department of Pulmonary Circulation, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Institute of Science Tokyo"},{"name":"Department of Rheumatology, Ome Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Konda N, Sakai R, Saeki K, Matsubara Y, Nakamura Y, Miyamae T, et al. Nationwide clinical and epidemiological study of large-vessel vasculitis in Japan in 2017. <i>Mod Rheumatol<\/i> 2023; 34: 167\u2013174.","DOI":"10.1093\/mr\/road019"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yajima M, Numano F, Park YB, Sagar S. Comparative studies of patients with Takayasu arteritis in Japan, Korea and India: Comparison of clinical manifestations, angiography and HLA-B antigen. <i>Jpn Circ J<\/i> 1994; 58: 9\u201314.","DOI":"10.1253\/jcj.58.9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Goel R, Gribbons KB, Carette S, Cuthbertson D, Hoffman GS, Joseph G, et al. Derivation of an angiographically based classification system in Takayasu\u2019s arteritis: An observational study from India and North America. <i>Rheumatology (Oxford)<\/i> 2020; 59: 1118\u20131127.","DOI":"10.1093\/rheumatology\/kez421"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. <i>J Rheumatol<\/i> 2020; 47: 255\u2013263.","DOI":"10.3899\/jrheum.181219"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, et al. Organ damage and quality of life in Takayasu arteritis: Evidence from a national registry analysis. <i>Circ J<\/i> 2024; 88: 285\u2013294.","DOI":"10.1253\/circj.CJ-23-0656"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of giant cell arteritis and takayasu arteritis. <i>Arthritis Rheumatol<\/i> 2021; 73: 1349\u20131365.","DOI":"10.1002\/art.41774"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al. JCS 2017 Guideline on management of vasculitis syndrome: Digest version. <i>Circ J<\/i> 2020; 84: 299\u2013359.","DOI":"10.1253\/circj.CJ-19-0773"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. <i>BMJ<\/i> 2008; 336: 924\u2013926.","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"9","unstructured":"9. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5 (updated August 2024) edn. Cochrane, 2024."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. <i>BMJ<\/i> 2019; 366: l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). <i>Ann Rheum Dis<\/i> 2018; 77: 348\u2013354.","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wang J, Kong X, Ma L, Ding Z, Chen H, Chen R, et al. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: An open-label study. <i>Rheumatology (Oxford)<\/i> 2024; 63: 1359\u20131367.","DOI":"10.1093\/rheumatology\/kead387"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Padiyar S, Danda D, Goel R, Joseph E, Nair AM, Joseph G, et al. Clinical and angiographic outcomes of mycophenolate versus methotrexate in South Asian patients of Takayasu arteritis: Results from an open-label, outcome-assessor blinded randomized controlled trial. <i>Mod Rheumatol<\/i> 2023; 34: 175\u2013181.","DOI":"10.1093\/mr\/roac157"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. <i>Arthritis Rheumatol<\/i> 2017; 69: 846\u2013853.","DOI":"10.1002\/art.40037"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. <i>N Engl J Med<\/i> 2017; 377: 317\u2013328.","DOI":"10.1056\/NEJMoa1613849"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2016; 387: 1921\u20131927.","DOI":"10.1016\/S0140-6736(16)00560-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. <i>Ann Intern Med<\/i> 2007; 146: 621\u2013630.","DOI":"10.7326\/0003-4819-146-9-200705010-00004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. <i>Ann Rheum Dis<\/i> 2008; 67: 625\u2013630.","DOI":"10.1136\/ard.2007.082115"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puechal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. <i>Ann Rheum Dis<\/i> 2014; 73: 2074\u20132081.","DOI":"10.1136\/annrheumdis-2013-203586"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. <i>Arthritis Rheumatol<\/i> 2017; 69: 837\u2013845.","DOI":"10.1002\/art.40044"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis Rheum<\/i> 2002; 46: 1309\u20131318.","DOI":"10.1002\/art.10262"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, double-blind, placebo-controlled trial. <i>Ann Intern Med<\/i> 2001; 134: 106\u2013114.","DOI":"10.7326\/0003-4819-134-2-200101160-00010"},{"key":"23","unstructured":"23. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). <i>Clin Exp Rheumatol<\/i> 2001; 19: 495\u2013501."},{"key":"24","unstructured":"24. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. <i>J Rheumatol<\/i> 2000; 27: 1484\u20131491."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. <i>Arthritis Rheum<\/i> 2006; 54: 3310\u20133318.","DOI":"10.1002\/art.22163"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): A randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Rheumatol<\/i> 2023; 5: e341\u2013e350.","DOI":"10.1016\/S2665-9913(23)00101-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis. <i>Ann Rheum Dis<\/i> 2022; 81: 1647\u20131653.","DOI":"10.1002\/art.42325"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sugihara T, Harigai M, Uchida HA, Yoshifuji H, Maejima Y, Ishizaki J, et al. Performance of the modified 2022 ACR\/EULAR giant cell arteritis classification criteria without age restriction for discriminating from Takayasu arteritis. <i>Arthritis Res Ther<\/i> 2025; 27: 19.","DOI":"10.1186\/s13075-025-03486-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). <i>Circ J<\/i> 2011; 75: 474\u2013503.","DOI":"10.1253\/circj.CJ-88-0007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: Final results of the randomized controlled phase 3 TAKT study. <i>Rheumatology (Oxford)<\/i> 2020; 59: 2427\u20132434.","DOI":"10.1093\/rheumatology\/kez630"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Harigai M, Miyamae T, Hashimoto H, Yoshida A, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA(R) (ACT)-Bridge study. <i>Mod Rheumatol<\/i> 2023; 33: 998\u20131006.","DOI":"10.1093\/mr\/roac099"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shirai T, Ishii T, Okazaki S, Shirota Y, Ishii Y, Sato H, et al. Active withdrawal of corticosteroids using tocilizumab and its association with autoantibody profiles in relapsed Takayasu arteritis: A multicentre, single-arm, prospective study (the Ab-TAK study). <i>Front Immunol<\/i> 2024; 15: 1473100.","DOI":"10.3389\/fimmu.2024.1473100"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shirai T. Common autoantibody among Takayasu arteritis and ulcerative colitis: A possible pathophysiology that includes gut-vessel connection in vascular inflammation. <i>JMA J<\/i> 2023; 6: 265\u2013273.","DOI":"10.31662\/jmaj.2023-0038"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mertz P, Kleinmann JF, Lambert M, Puechal X, Bonnin A, Boulon C, et al. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study. <i>Autoimmun Rev<\/i> 2020; 19: 102634.","DOI":"10.1016\/j.autrev.2020.102634"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Arita Y, Ishibashi T, Nakaoka Y. Current immunosuppressive treatment for Takayasu arteritis. <i>Circ J<\/i> 2024; 88: 1605\u20131609.","DOI":"10.1253\/circj.CJ-23-0780"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. <i>Mod Rheumatol<\/i> 2024; 34: 775\u2013783.","DOI":"10.1093\/mr\/road074"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A phase 3 trial of upadacitinib for giant-cell arteritis. <i>N Engl J Med<\/i> 2025; 392: 2013\u20132024.","DOI":"10.1056\/NEJMoa2413449"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/10\/90_CJ-25-1129\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:28:29Z","timestamp":1790393309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/10\/90_CJ-25-1129\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-1129","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"CJ-25-1129"}}